Contributor to Committee Publication |
| Ethics and Human Rights Committee, American College of Physicians American College of Physicians: Ethics Manual, 5th Edition Fifth Edition. American College of Physicians, 2004 | 2004 |
Photo Case and summary |
| Herrin VE, Files JC Renal hemosiderosis due to intravascular hemolysis Photo case in Blood, 94(7):2332 | 1999 |
Letter |
| Conwill DE, Sorey WH, Herrin VE, Life support for patients with cervical-level quadriplegia. The New England journal of medicine, 1993 Aug 26;329(9):664 | 1993 |
Journal Article |
| Braddock CH, Snyder L, Neubauer RL, Fischer GS, American College of Physicians Ethics, Professionalism, and Human Rights Committee and Society for General Internal Medicine Ethics Committee The patient-centered medical home: an ethical analysis of principles and practice. Journal of General Internal Medicine. 2013; 28(1):141-6. | 2013 |
| Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN. A Gynecologic Oncology Group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology and Immunotherapeutics. 2012; 61(3):373-84. | 2012 |
| Bailey JH, Beacham T, Weeks K, Smith CC, Horn M, Herrin VE. Can the Delta stop singing the blues? Journal of the Mississippi State Medical Association. 2010; 51(9):242-246. | 2010 |
| Sumrall A, Herrin V. Recurrent, transformed non-Hodgkin's lymphoma presenting as chiasmal syndrome with hyperprolactinemia and hypopituitarism. Journal of the Mississippi State Medical Association. 2010; 51(2):35-36. | 2010 |
| Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, Bernstein SA, Berzofsky JA, Khleif SN. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. Journal of Translational Medicine. 2010; 8:8. | 2010 |
| Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, Hamilton M, Bernstein S, Venzon D, Gause B, Marincola F, Khleif SN. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunology and Immunotherapeutics. 2008; 57(9):1413-20. | 2008 |
| Herrin VE, Gray GC Decreasing rates of hospitalization for varicella among young adults The Journal of Infectious Diseases 174:835-8, 1996 | 1996 |
| Herrin VE, Fato M Ethics case study: Must you disclose mistakes made by other physicians? ACP Observer, 23:11, November 2003 | 2003 |
| Herrin V Ethics case study: Do you need to talk to patients about mistakes? ACP-ASIM Observer, 22:3, March 2002 | 2002 |
Herrin V, Poon P Ethics case study: Talking about organ procurement
when one of your patients dies ACP-ASIM Observer, 20:2 | 2000 |
| Pepper DJ, Schweinfurth M, Herrin VE, The effect of new duty hours on resident academic performance and adult resuscitation outcomes. The American journal of medicine, 2014 Apr;127(4):337-42 | 2014 |
| Braddock CH 3rd, Snyder L, Neubauer RL, Fischer GS, American College of Physicians Ethics, Professionalism and Human Rights Committee and The Society of General Internal Medicine Ethics Committee, The patient-centered medical home: an ethical analysis of principles and practice. Journal of general internal medicine, 2013 Jan;28(1):141-6 | 2013 |
| Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN, A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer immunology, immunotherapy : CII, 2012 Mar;61(3):373-84 | 2012 |
| Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, Smith WR, Galacteros F, Kutlar A, Hull JH, Stocker JW, ICA-17043-10 Study Investigators, Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). British journal of haematology, 2011 Apr;153(1):92-104 | 2011 |
| Sumrall A, Herrin V, Recurrent, transformed non-Hodgkin's lymphoma presenting as chiasmal syndrome with hyperprolactinemia and hypopituitarism. Journal of the Mississippi State Medical Association, 2010 Feb;51(2):35-6 | 2010 |
| Bailey JH, Beacham T, Weeks K, Smith CC, Horn M, Herrin V, Can the Delta stop singing the blues? Journal of the Mississippi State Medical Association, 2010 Sep;51(9):242-6 | 2010 |
| Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, Hamilton M, Bernstein S, Venzon D, Gause B, Marincola F, Khleif SN, Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer immunology, immunotherapy : CII, 2008 Sep;57(9):1413-20 | 2008 |
| Herrin VE, Thigpen JT, High-dose chemotherapy in ovarian carcinoma. Seminars in oncology, 1999 Feb;26(1):99-105 | 1999 |
| Herrin VE, Gray GC, Decreasing rates of hospitalization for varicella among young adults. The Journal of infectious diseases, 1996 Oct;174(4):835-8 | 1996 |
| Herrin VE, Thigpen JT, Chemotherapy for ovarian cancer: current concepts. Seminars in surgical oncology, 1999 Oct-Nov;17(3):181-8 | |
Review Article |
| Herrin VE, Thigpen JT Recent developments in the treatment of recurrent ovarian carcinoma Advances in Oncology, 16(3):21-29, 2000 | 2000 |
| Herrin VE, Thigpen JT Chemotherapy for ovarian cancer: current concepts Seminars in Surgical Oncology, 17(3):181-188 | 1999 |
| Herrin VE, Thigpen JT High-dose chemotherapy in ovarian carcinoma Seminars in Oncology 26 (1):99-105 | 1999 |
| Herrington JM, Herrin VE, Elkins S Cancer basics The Mississippi Psychologist 24(2): 9, 18-19 | 1999 |
Abstracts |
| Evans J, Herrin V. Hodgkin's lymphoma presenting with epidural spinal involvement. Journal of Investigative Medicine. 2014; 62:530. | 2014 |
| Hansen DK, Milner CP, Zamora A, Albrecht S, Webb R, Buck T, Herrin V. When a white count is needed the most: The first case report of a neutropenic patient surviving sporopachydermia cereana fungemia. Journal of Investigative Medicine. 2014; 62:431. | 2014 |
| Henegan JC, Herrin V. Travel medicine and hemoglobinopathies. Journal of Investigative Medicine. 2014; 62:438. | 2014 |
| Williams JC, Herrin V. Only the strong survive: A case of primary hemophagocytic lymphohistiocytosis. Journal of Investigative Medicine. 2014; 62:465. | 2014 |
| Wilkinson KJ, Herrin V, Lam JT. Go with the flow: Plasma cell leukemia in a patient with leukocytosis, hypercalcemia, and renal failure. Journal of Investigative Medicine. 2014;62:465 | 2014 |
| Eubanks J, Herrin V. Acute promyelocytic leukemia presenting with gingival hyperplasia. Journal of Investigative Medicine. 2014; 62:529. | 2014 |
| Nagireddy S, Herrin VE. IgG4-related testicular pseudotumor. Journal of Investigative Medicine. 2013; 61(2):406. | 2013 |
| Nagireddy S, Milner C, Lam J, Herrin VE. Late onset post-transplant lymphoproliferative disorder, a diffuse large B-cell lymphoma with cyclin D1 expression and complicated by pregnancy. Journal of Investigative Medicine. 2013; 61(2):504. | 2013 |
| Pepper DJ, Schweinfurth M, Herrin VE. Effects of new ACGME duty hours on resident academic performance and patient outcomes during code blues and rapid responses. Journal of Investigative Medicine. 2013; 61(2):499. | 2013 |
| Tullos BW, Gaugler SM, Thigpen SC, Henson Z, Herrin VE. Now you see it, now you don't: Evans syndrome in a patient suspected to have lymphoma. Journal of the Mississippi State Medical Association. 2012; 53(11):365-366. | 2012 |
| Cassell M, Herrin V. Case report and review of the literature on episodic angioedema with eosinophilia (Gleich Syndrome). Journal of Investigative Medicine. 2012; 60(1):358. | 2012 |
| Gatewood JB, Herrin V, Elkins S. A case report of a successful pregnancy in a patient with paroxysmal nocturnal hemoglobinuria receiving eculizamab. Journal of Investigative Medicine. 2011; 59(2):521. | 2011 |
| Gatewood JB, Herrin V, Elkins S, Biglane B, Jackson C A case report of widely metastatic histiocytic sarcoma Journal of Investigative Medicine. 2010; 58(2):399. | 2010 |
| Sumrall AL, Herrin V. Recurrent, transformed non-Hodgkin's lymphoma presenting as chiasmal syndrome with hyperprolactinemia and hypopituitarism. Journal of Investigative Medicine. 2010; 58(2):403. | 2010 |
| Persing BE, Williams JC, Elkins SL, Herrin VE A Case Report of Papillomatosis with Progression to Multifocal Squamous Cell Cancer of the Lung Journal of Investigative Medicine. 2009; 57(1):406. | 2009 |
| Persing BE, Elkins SL, Herrin VE A Case Report of IgE Multiple Myeloma Journal of Investigative Medicine. 2008; 56(1):396. | 2008 |
| Herrin VE, Achtar MS, Steinberg SM, Whiteside TL, Wieckowski E, Czystowska M, Visus C, Berzofsky JA, Khleif SN A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide-pulsed dendritic cells in high risk ovarian cancer patients Journal of Clinical Oncology. 2007; 25(18S):3011. | 2007 |
| Achtar MS, Toubaji A, Herrin VE, Hamilton M, Gause B, Steinberg S, Grollman F, Bernstein S, Khleif SN Phase II clinical trial of mutant ras vaccine peptide in combination with GM-CSF and IL-2 in advanced cancer patients Journal of Clinical Oncology. 2007; 25(18S):3067. | 2007 |
| Bigelow CL, Elkins SL, Herrin VE, Hardy CL, Files JC Determination of alemtuzumab dose for reduced intensity conditioning in allogeneic transplantation Biology of Blood and Marrow Transplantation. 2007;13(2)suppl 83. | 2007 |
| Arledge S, Elkins S, Bigelow C, Files J, Herrin V, Hardy C Reduced Intensity Conditioning Using Alemtuzumab in Allogeneic Hematopoietic Transplantation Journal of Investigative Medicine. 2007; 55(1):283. | 2007 |
| Persing B, Herrin V, Elkins S, Files J, Bigelow C An Unusual Presentation of Diffuse Large B-Cell Lymphoma Journal of Investigative Medicine. 2007; 55(1):268. | 2007 |
| Hardy CL, Files JC, Bigelow CL, Elkins SL, Herrin VE. Alemtuzumab dosing by recipient weight is important for reduced-intensity conditioning for allogeneic transplantation. Journal of Investigative Medicine. 2007; 55(1):302-303. | 2007 |
| Wright A, Elkins S, Files J, Bigelow C, Herrin V, Sample M. Thromboembolism in multiple myeloma patients receiving thalidomide combination chemotherapy. Journal of Investigative Medicine. 2007; 55(1):302. | 2007 |
| Achtar MS, Ibrahim R, Herrin VE, Rahma O, Gause B, Grollman F, Bernstein SA, Maruffi CM, Berzofsky JA, Khleif SN Vaccine therapy with human papillomavirus 16 E7 peptide-pulsed PBMC’s in locally advanced or metastatic cervical cancer Journal of Clinical Oncology. 2005; 23(16S):2522. | 2005 |
| Ibrahim RA, Achtar MS, Herrin VE, Gause B, Bernstein SA, Grollman F, Contoise D, Steinberg S, Berzofsky JA, Khleif SN Autologous PBMC’s pulsed with HPV16 E6 as an immunotherapeutic for patients with advanced cervical cancer Journal of Clinical Oncology. 2005; 23 (16S):2508. | 2005 |
| Toubaji A, Achtar MS, Herrin VE, Provenzano M, Bernstein S, Brent-Steel T, Marincola F, Khleif SN. Immunotherapeutic role of mutant ras peptide-based vaccine as an adjuvant in pancreatic and colorectal cancer. Journal of Clinical Oncology. 2005; 23(16S):2573. | 2005 |
| Ibrahim RA, Achtar MS, Herrin VE, Gause B, Bernstein SA, Brent-Steel TB, Maruffi CM, Berzofsky JA, Khleif SN Mutant p53 vaccination of patients with advanced cancers generates specific immunologic responses Proceedings of the American Society of Clinical Oncology. 2004;2521. | 2004 |
| Achtar MS, Ibrahim R, Herrin VE, Gause B, Bernstein SA, Brent-Steel TB, Maruffi CM, Berzofsky JA, Khleif SN. Vaccine therapy with tumor specific mutated VHL peptides in adult cancer patients with renal cell carcinoma. Proceedings of the American Society of Clinical Oncology. 2004;2589. | 2004 |
| Herrin VE, Behrens R, Achtar M, Bernstein S, Brent-Steel T, Maruffi C, Whiteside T, Wieckowski E, Berzofsky J, Khleif SN Wild-type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinoma Proceedings of the American Society of Clinical Oncology. 2003; 22:678. | 2003 |
| Behrens R, Achtar M, Bernstein S, Brent-Steel T, Herrin VE, Maruffi C, Whiteside T, Khleif SN Phase I/II mutant p53 vaccination in advanced malignancies Proceedings of the American Society of Clinical Oncology. 2003; 22:186. | 2003 |
| Achtar M, Behrens R, Herrin VE, Gause B, Bernstein S, Brent-Steel T, Maruffi C, Yancey M, Khleif SN Mutant ras vaccine in advanced cancers Proceedings of the American Society of Clinical Oncology. 2003; 22:169. | 2003 |
| Gause B, Behrens R, Achtar M, Herrin VE, Bernstein S, Brent-Steel T, Yancey M, Maruffi C, Khleif SN An adjuvant phase II pilot trial of mutant ras peptide vaccine in stage II and III pancreatic and Duke C and D colorectal cancer Proceedings of the American Society of Clinical Oncology. 2003; 22 | 2003 |
| Behrens RJ, Bernstein SA, Gilliom MF, Grollman FR, Hamilton JM, Herrin VE, Maruffi CM, Khleif SN Phase II adjuvant therapy of pancreas and colorectal cancer with mutant ras vaccine Journal of Clinical Oncology | 2002 |
| Herrin VE, Suwannaroj S, McMurray RW Gonadal steroid modulation of leukemic cell line responses to chemotherapeutic agents in vitro Blood, 92(10) (suppl 1, part 2):211b, 1998 | 1998 |
| Herrin VE, Larkins P, Gray GC Decreasing rates of hospitalization for varicella among young adults San Diego Biostatistics and Epidemiology Research Exchange, 1996 (poster) | 1996 |
Thesis |
| Herrin VE The campaigns of a boy general: The Civil War career of Adelbert Ames Mississippi College | 1990 |
Book Chapter |
| Thigpen T, Herrin VE Recent developments in the treatment of recurrent ovarian carcinoma Rubin, Sutton (eds), Ovarian Cancer, Second Edition, Lippincott, Williams and Wilkins: Philadelphia, 2001 | 2001 |
| Herrin VE, Thigpen JT Germ cell tumors of the ovary Chapter 56 in Textbook of Uncommon Cancer, 2nd edition, (pp. 671-680), Wiley: Chichester | 1999 |
Letter to the Editor |
| Conwill DE, Sorey WH, Herrin VE Life support for patients with cervical-level quadriplegia The New England Journal of Medicine 329(9):664, 1993 | 1993 |
Electronic Publications |
| Herrin VE, Thigpen JT Second-line treatment for epithelial ovarian cancer UpToDate article at www.uptodate.com, 2002 | 2002 |
| Herrin VE, Files JC Hypereosinophilic syndrome Chapter in Medicine, Ob/Gyn, Psychiatry and Surgery, an on-line textbook at www.emedicine.com, 2000 | 2000 |
Clinical Trial |
| Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, Bernstein SA, Berzofsky JA, Khleif SN, A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. Journal of translational medicine, 2010 Jan 28;8:8 | 2010 |
